LAIDLOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H62O12
Molecular Weight	698.881
Optical Activity	UNSPECIFIED
Defined Stereocenters	17 / 17
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]2(C)CC[C@@]([H])(O2)[C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@]([H])(O4)[C@@H](C)[C@@H](OC(=O)CC)[C@H](C)C(O)=O)O3)[C@@]5([H])O[C@@](O)(CO)[C@H](C)C[C@@H]5C

InChI

InChIKey=ZNBNBTIDJSKEAM-NISBWGIBSA-N

InChI=1S/C37H62O12/c1-10-28(40)45-30(24(7)33(41)42)23(6)31-22(5)25(39)17-36(47-31)14-13-34(8,49-36)27-11-12-35(9,46-27)32-20(3)16-26(44-32)29-19(2)15-21(4)37(43,18-38)48-29/h19-27,29-32,38-39,43H,10-18H2,1-9H3,(H,41,42)/t19-,20-,21+,22+,23-,24-,25-,26+,27+,29-,30+,31-,32+,34-,35-,36+,37-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C37H62O12
Molecular Weight	698.881
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	17 / 17
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/pro/cattlyst.html | https://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm132769.htm | https://www.ncbi.nlm.nih.gov/pubmed/11099233 | https://www.ncbi.nlm.nih.gov/pubmed/4452661

Laidlomycin is a polycyclic polyether antibiotic which possesses an inhibitory activity against various mycoplasma species}, and is effective in controlling coccidiosis in chickens. It is also known as selectively inhibiting the migration of hemagglutinin glycoprotein from Golgi apparatus to the cell surface in measles virus). Laidlomycin inhibited growth of some Gram-positive bacteria only at high concentrations such as 50-100 ug/ml, but was not active against Gram-negative bacteria, yeast and fungi even at concentration of 1,000 ug/ml. In broth dilution, laidlomycin was active against several illycoplasmas and most active against the sterol-nonrequiring mycoplasma, Acholeplasma laidlawii. Under the brand name Cattlyst Laidlomycin is indicated for improved feed efficiency and increased rate of weight gain in cattle fed in confinement for slaughter.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus 1 33 Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11099233	Inhibitor 8297
Streptococcus 2 Target ID: CHEMBL612313 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9814916	Inhibitor 8297
ion transport 4 Target ID: GO:0006811 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9814916 \| https://www.ncbi.nlm.nih.gov/pubmed/14503688	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11099233	Primary		Basic research	Unknown Approved Use Unknown
Growth and weight problems in cattle 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10682819 https://www.ncbi.nlm.nih.gov/pubmed/8586605	Primary		Approved 8429	Cattlyst Approved Use For improved feed efficiency and increased rate of weight gain in cattle fed in confinement for slaughter Launch Date 1994

PubMed

Title	Date	PubMed
Intake, digestion, and digestive characteristics of Neotyphodium coenophialum-infected and uninfected fescue by heifers offered hay diets supplemented with Aspergillus oryzae fermentation extract or laidlomycin propionate.	2002 Jan	11831521
Effects of the antibiotic ionophores monensin, lasalocid, laidlomycin propionate and bambermycin on Salmonella and E. coli O157:H7 in vitro.	2003	12534812
Ionophores have limited effects on jejunal glucose absorption and energy metabolism in mice.	2003 Aug	12926789
Effect of feeding the ionophores monensin and laidlomycin propionate and the antimicrobial bambermycin to sheep experimentally infected with E. coli O157:H7 and Salmonella typhimurium.	2003 Feb	12643501
Ionophores: their use as ruminant growth promotants and impact on food safety.	2003 Sep	14503688
Inhibition of resistance plasmid transfer in Escherichia coli by ionophores, chlortetracycline, bacitracin, and ionophore/antimicrobial combinations.	2004 Apr-Jun	15283418
Production and biological activity of laidlomycin, anti-MRSA/VRE antibiotic from Streptomyces sp. CS684.	2007 Feb	17342048
Monoclonal antibody production and immunochemical detection of polyether antibiotics.	2009 Mar	19387589

Patents

Sample Use Guides

In Vivo Use Guide

Laidlomycin propionate promix, 50 g of laidlomycin propionate potassium per pound. Laidlomycin propionate premix should be admixed into feed and fed at a dietary concentration of 5 to 10 g of laidlomycin propionate/ton of feed (90% dry matter basis) to provide not less than 30 nor more than 150 mg/animal/day.

Route of Administration: Oral

In Vitro Use Guide

Laidlomycin propionate (16.2 mM) decreased (P < 0.02) glucose absorption, as estimated by H3-3-O-methyl glucose uptake compared with all other treatments of murine jejunal rings, whereas laidlomycin propionate (1.62 mM) increased (P = 0.032) jejunal DM content compared with 16.2 mM laidlomycin propionate.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:13:25 GMT 2023` Edited by `admin` on `Fri Dec 15 17:13:25 GMT 2023`
Record UNII	MI3S6ZF5QE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LAIDLOMYCIN

Official Name

English

MONENSIN, 16-DEETHYL-3-O-DEMETHYL-16-METHYL-3-O-(1-OXOPROPYL)-

Common Name

English

LAIDLOMYCIN [MI]

Common Name

English

laidlomycin [INN]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 558.305